Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) (KEYNOTE-B15)
Muscle Invasive Bladder Cancer
About this trial
This is an interventional treatment trial for Muscle Invasive Bladder Cancer focused on measuring Programmed cell death 1 (PD-1), Programmed Death-Ligand 1 (PD-L1), Programmed Death-Ligand 2 (PD-L2), Pelvic Lymph Node Dissection (PLND), Radical Cystectomy (RC)
Eligibility Criteria
Inclusion Criteria:
- Have a histologically confirmed diagnosis of urothelial carcinoma (UC) / muscle invasive bladder cancer (MIBC) (T2-T4aN0M0 or T1-T4aN1M0) with predominant (≥50%) urothelial histology
- Have clinically non-metastatic bladder cancer (N≤1 M0) determined by imaging (computed tomography (CT) or magnetic resonance imaging (MRI) of the chest/abdomen/pelvis
- Be deemed eligible for Radical Cystectomy (RC) + Pelvic Lymph Node Dissection (PLND)
- Have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Have adequate organ function
Exclusion Criteria:
- Has a known additional malignancy that is progressing or has required active anti-cancer treatment ≤3 years of study randomization with certain exceptions
- Has received any prior systemic treatment for MIBC or non-invasive muscle bladder cancer (NMIBC - prior treatment for NMIBC with intravesical BCG/chemotherapy is permitted) or prior therapy with an anti- programmed cell death 1 (PD-1), anti-programmed cell death ligand 1/ ligand 2 (PD-L1/L2), or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
- Has ≥N2 disease or metastatic disease (M1) as identified by imaging
- Is cisplatin-ineligible, as defined by meeting any one of the cisplatin ineligibility criteria as per protocol
- Has received prior systemic anticancer therapy including investigational agents within 3 years of randomization or any radiotherapy to the bladder
- Has undergone partial cystectomy of the bladder to remove any NMIBC or MIBC
- Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention
- Has a diagnosis of immunodeficiency or has a known history of human immunodeficiency virus (HIV) infection. Hepatitis B infection or known active Hepatitis C infection
- Has a known psychiatric or substance abuse disorder
- Has had an allogenic tissue/solid organ transplant
- Has ongoing sensory or motor neuropathy Grade 2 or higher
- Has active keratitis (superficial punctate keratitis) or corneal ulcerations
- Has a history of uncontrolled diabetes defined as hemoglobin A1c (HbA1c) ≥8% or HbA1c 7% to <8% with associated diabetes symptoms
Sites / Locations
- Mayo Clinic in Arizona - Phoenix ( Site 0043)Recruiting
- St Joseph Heritage Healthcare-Oncology ( Site 0035)
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of UroRecruiting
- University of California San Francisco ( Site 0010)Recruiting
- Stanford University ( Site 0023)Recruiting
- University of Colorado, Anschutz Cancer Pavilion ( Site 0009)Recruiting
- UF Health ( Site 0031)Recruiting
- Indiana University Melvin and Bren Simon Cancer Center ( Site 0050)Recruiting
- University of Iowa Hospital and Clinics ( Site 0029)Recruiting
- University of Louisville, James Graham Brown Cancer Center ( Site 0022)Recruiting
- Icahn School of Medicine at Mount Sinai ( Site 0011)Recruiting
- White Plains Hospital ( Site 0039)Recruiting
- Duke University Medical Center ( Site 0017)Recruiting
- Wake Forest Baptist Health ( Site 0014)Recruiting
- Oregon Health and Science University ( Site 0028)Recruiting
- MidLantic Urology ( Site 0002)Recruiting
- Saint Francis Cancer Center ( Site 0008)Recruiting
- The University of Tennessee Medical Center ( Site 0034)
- UT Southwestern Medical Center ( Site 0003)Recruiting
- Houston Methodist Urology Associates ( Site 0033)Recruiting
- Urology of San Antonio ( Site 0020)Recruiting
- University of Wisconsin Hospital and Clinics ( Site 0037)Recruiting
- Hospital Británico de Buenos Aires-Oncology ( Site 1551)Recruiting
- Hospital Italiano de Buenos Aires ( Site 1554)Recruiting
- Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 1558)Recruiting
- Fundacion Estudios Clinicos-Oncology ( Site 1557)Recruiting
- Centro de Urología (CDU) ( Site 1552)Recruiting
- Asociación de Beneficencia Hospital Sirio Libanés ( Site 1553)Recruiting
- Macquarie University-MQ Health Clinical Trials Unit ( Site 1259)Recruiting
- Mater Hospital Brisbane ( Site 1257)
- Lyell McEwin Hospital ( Site 1252)Recruiting
- Frankston Hospital-Oncology and Haematology ( Site 1258)Recruiting
- MHAT "Uni Hospital" OOD ( Site 1154)Recruiting
- Complex Oncology Center Plovdiv ( Site 1151)Recruiting
- MHAT Central Onco Hospital OOD ( Site 1158)Recruiting
- MHAT Serdika ( Site 1152)Recruiting
- BC Cancer - Vancouver Center ( Site 0110)Recruiting
- CancerCare Manitoba ( Site 0108)Recruiting
- Moncton Hospital ( Site 0107)Recruiting
- Ottawa Hospital Research Institute ( Site 0109)Recruiting
- Jewish General Hospital ( Site 0106)Recruiting
- SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 1406)Recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University ( Site 1413)Recruiting
- Hunan Cancer Hospital ( Site 1403)Recruiting
- Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( SRecruiting
- Nantong Tumor Hospital-Urology ( Site 1405)
- Fudan University Shanghai Cancer Center-Urology department ( Site 1401)Recruiting
- Renji Hospital Shanghai Jiao Tong University School of Medicine ( Site 1402)Recruiting
- Fundación Colombiana de Cancerología Clínica Vida ( Site 1653)Recruiting
- Oncomédica S.A.S ( Site 1652)Recruiting
- Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 1654)Recruiting
- Fundación Cardiovascular de Colombia-Santander ( Site 1657)Recruiting
- Fundacion Valle del Lili- CIC ( Site 1656)Recruiting
- Klinički bolnički centar Sestre milosrdnice ( Site 1703)Recruiting
- Klinički bolnički centar Zagreb-Klinika za onkologiju ( Site 1701)Recruiting
- Klinički bolnički centar Osijek ( Site 1705)Recruiting
- Klinički Bolnički Centar Split-Oncology and Radiotherapy ( Site 1702)Recruiting
- Fakultni nemocnice u sv. Anny v Brne ( Site 0253)Recruiting
- Fakultni nemocnice Hradec Kralove-Klinika onkologie a radioterapie ( Site 0254)Recruiting
- Fakultni Nemocnice Olomouc ( Site 0251)Recruiting
- Fakultni Thomayerova nemocnice ( Site 0252)Recruiting
- CHU La Timone ( Site 0456)Recruiting
- CHU Jean Minjoz ( Site 0453)Recruiting
- CHU de Brest -Site Hopital Morvan ( Site 0461)Recruiting
- Institut Universitaire du Cancer Toulouse - Oncopole ( Site 0455)Recruiting
- CHU Limoges Hopital Dupuytren ( Site 0459)Recruiting
- Gustave Roussy ( Site 0467)Recruiting
- CHU GRENOBLE ALPES ( Site 0468)Recruiting
- Centre Hospitalier Regional du Orleans ( Site 0463)Recruiting
- Polyclinique du Bois ( Site 0458)Recruiting
- Hopital Diaconesses Croix Saint Simon ( Site 0465)Recruiting
- Universitaetsklinikum Freiburg ( Site 0512)Recruiting
- Universitaetsklinik fuer Urologie ( Site 0501)Recruiting
- Caritas Krankenhaus St. Josef ( Site 0502)Recruiting
- Universitaetsklinikum Wuerzburg ( Site 0520)Recruiting
- Kath. Krankenhaus Marienhospital. Universitaetsklinik ( Site 0511)Recruiting
- Universitaetsklinikum Muenster ( Site 0516)Recruiting
- Krankenhaus Martha Maria Halle-Doelau ( Site 0507)Recruiting
- Universitaetsklinikum Carl Gustav Carus ( Site 0509)Recruiting
- Vivantes Klinikum Am Urban ( Site 0519)Recruiting
- UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 0305)Recruiting
- General Hospital of Athens "Alexandra" ( Site 0303)Recruiting
- Athens Medical Center ( Site 0304)Recruiting
- ATTIKON GENERAL UNIVERSITY HOSPITAL ( Site 0301)Recruiting
- University General Hospital of Larissa ( Site 0302)Recruiting
- Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ ( Site 1010)Recruiting
- Jász-Nagykun-Szolnok Vármegyei Hetényi Géza Kórház ( Site 1002)Recruiting
- Debreceni Egyetem Klinikai Kozpont ( Site 1006)Recruiting
- Rambam Health Care Campus-Oncology ( Site 0751)Recruiting
- Hadassah Medical Center-Oncology ( Site 0757)Recruiting
- Meir Medical Center-oncology ( Site 0754)Recruiting
- Rabin Medical Center-Oncology ( Site 0752)Recruiting
- Sheba Medical Center-ONCOLOGY ( Site 0753)Recruiting
- Sourasky Medical Center-Oncology ( Site 0755)Recruiting
- Yitzhak Shamir Medical Center-Oncology ( Site 0756)Recruiting
- Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0588)Recruiting
- Presidio Ospedaliero Santa Maria delle Grazie ( Site 0599)Recruiting
- AOU San Luigi Gonzaga di Orbassano ( Site 0595)Recruiting
- Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento ( Site 0598)Recruiting
- Azienda Ospedaliero Universitaria delle Marche-Clinica Oncologica ( Site 0593)Recruiting
- Ospedale Cannizzaro ( Site 0590)Recruiting
- IRCCS Ospedale San Raffaele ( Site 0596)Recruiting
- Istituto Oncologico Veneto IRCCS-Oncologia Medica 1 ( Site 0600)Recruiting
- Nagoya University Hospital ( Site 1512)Recruiting
- Hirosaki University Hospital ( Site 1501)Recruiting
- University of Tsukuba Hospital ( Site 1502)Recruiting
- Kanazawa University Hospital ( Site 1509)Recruiting
- Kitasato University Hospital ( Site 1506)Recruiting
- Yokohama City University Medical Center ( Site 1508)
- Kanagawa Cancer Center ( Site 1507)Recruiting
- Tohoku University Hospital ( Site 1503)Recruiting
- Hamamatsu University Hospital ( Site 1511)Recruiting
- Gifu University Hospital ( Site 1513)Recruiting
- Nagasaki University Hospital ( Site 1517)Recruiting
- Okayama University Hospital ( Site 1516)Recruiting
- Osaka International Cancer Institute ( Site 1514)Recruiting
- Osaka Metropolitan University Hospital ( Site 1515)Recruiting
- Tokyo Medical and Dental University Hospital ( Site 1505)Recruiting
- Keio University Hospital ( Site 1504)Recruiting
- Toyama University Hospital ( Site 1510)Recruiting
- Chonnam National University Hwasun Hospital ( Site 1353)Recruiting
- Seoul National University Bundang Hospital ( Site 1355)Recruiting
- Asan Medical Center ( Site 1352)Recruiting
- Kyungpook National University Chilgok Hospital ( Site 1354)Recruiting
- Gachon University Gil Medical Center ( Site 1356)Recruiting
- Korea University Anam Hospital ( Site 1357)Recruiting
- Seoul National University Hospital ( Site 1351)Recruiting
- University Malaya Medical Centre ( Site 0352)Recruiting
- Hospital Pulau Pinang ( Site 0355)Recruiting
- Sarawak General Hospital ( Site 0351)Recruiting
- Sunway Medical Centre ( Site 0353)Recruiting
- THE MEDICAL CITY ILOILO-The Medical City Iloilo - Clinical and Translational Research Institute-IloRecruiting
- Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu ( Site 1058)Recruiting
- Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1057)Recruiting
- Narodowy Instytut Onkologii ( Site 1051)Recruiting
- Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1053)Recruiting
- Clinical Research Center Medic-R ( Site 1061)Recruiting
- Szpital Wojewodzki im. Mikolaja Kopernika ( Site 1055)Recruiting
- Centro Hospitalar e Universitario de Coimbra ( Site 0406)Recruiting
- Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0409)Recruiting
- CHLO, EPE - Hospital de Sao Francisco Xavier ( Site 0401)Recruiting
- Hospital Geral de Santo Antonio ( Site 0408)Recruiting
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1102)Recruiting
- Cardiomed SRL Cluj-Napoca ( Site 1101)Recruiting
- Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 1103)Recruiting
- SC Radiotherapy Center Cluj SRL ( Site 1108)Recruiting
- S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1107)Recruiting
- Policlinica Oncomed SRL ( Site 1106)Recruiting
- SC Focus Lab Plus SRL ( Site 1104)Recruiting
- Altay Regional Oncology Dispensary ( Site 0851)
- National Medical Research Radiology Centre ( Site 0869)
- National Medical Research Centre of Oncology named after N.N. Blokhin ( Site 0865)
- First Moscow State Medical University n.a. I.M.Sechenov ( Site 0871)
- Volga District Medical Center ( Site 0876)
- St.Petersburg Clinical Hospital RAS ( Site 0864)
- St.Petersburg State Medical Univ. n.a. acad. I.P.Pavlov ( Site 0856)
- Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 0852)
- Sverdlovsk Regional Oncology Hospital ( Site 0867)
- Sverdlovsky Regional Clinical hospital #1 ( Site 0868)
- Volgograd Regional Uronephrological Center ( Site 0870)
- Tan Tock Seng Hospital ( Site 0704)Recruiting
- Wits Clinical Research ( Site 0603)Recruiting
- Steve Biko Academic Hospital ( Site 0601)Recruiting
- Groote Schuur Hospital ( Site 0602)Recruiting
- Hospital Universitario Central de Asturias ( Site 0654)Recruiting
- Hospital Germans Trias i Pujol. ICO de Badalona ( Site 0658)Recruiting
- Xarxa Assistencial Universitaria Manresa ( Site 0655)Recruiting
- Institut Català d'Oncologia (ICO) - Girona ( Site 0653)Recruiting
- CHUS - Hospital Clinico Universitario-Servicio de Oncologia ( Site 0660)Recruiting
- Hospital Universitario Insular de Gran Canaria ( Site 0657)Recruiting
- Fundación Instituto Valenciano de Oncología-Oncologico ( Site 0662)Recruiting
- Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0661)Recruiting
- Hospital Clinico Universitario San Carlos de Madrid ( Site 0651)Recruiting
- Hospital Virgen del Rocio ( Site 0659)Recruiting
- Chang Gung Memorial Hospital at Kaohsiung ( Site 1203)Recruiting
- China Medical University Hospital ( Site 1202)Recruiting
- Taipei Veterans General Hospital ( Site 1201)Recruiting
- I.I. Mechnykov Dnipropetrovsk Regional Clinical Hospital ( Site 0959)
- MI Clinical oncology dispensary of Dnipropetrovsk regional council ( Site 0954)
- Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval ( Site 0952)
- MNPE Regional Center of Oncology ( Site 0955)Recruiting
- Municipal Non-profit Enterprise of Kharkiv Regional Council RCSDRPP ( Site 0965)
- Lviv Oncology Regional Treatment and Diagnostic Center ( Site 0960)
- Zhytomyr Regional Oncology Center ( Site 0961)
- Torbay Hospital ( Site 1804)Recruiting
- St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1801)Recruiting
- Imperial College Healthcare NHS Foundation Trust - St Mary's Hospital ( Site 1802)Recruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm A: Perioperative EV+ Pembrolizumab and RC + PLND
Arm B: Standard of Care (SOC)-Neoadjuvant chemotherapy (gemcitabine + cisplatin) and RC + PLND
Participants receive 4 cycles (each cycle length = 21 days) of EV intravenous (IV) infusion plus pembrolizumab IV infusion preoperatively, followed by RC + PLND, followed by 5 cycles of adjuvant EV IV infusion plus 13 cycles of adjuvant pembrolizumab IV infusion postoperatively. The total treatment duration is up to approximately 1 year.
Participants receive 4 cycles (each cycle length = 21 days) of standard of care (SOC) chemotherapy (gemcitabine IV infusion plus cisplatin IV infusion) preoperatively, followed by RC + PLND. The total treatment duration is up to approximately 3 months.